TCM
TCG Crossover Management Portfolio holdings
AUM
$876M
This Quarter Return
+18.81%
1 Year Return
+23.66%
3 Year Return
+996.72%
5 Year Return
–
10 Year Return
–
AUM
$1.18B
AUM Growth
+$1.18B
(+23%)
Cap. Flow
+$77.2M
Cap. Flow
% of AUM
6.54%
Top 10 Holdings %
Top 10 Hldgs %
58.4%
Holding
38
New
6
Increased
2
Reduced
5
Closed
2
Top Buys
| 1 |
Xencor
XNCR
|
$48.8M |
| 2 |
THRD
Third Harmonic Bio
THRD
|
$32.7M |
| 3 |
Fulcrum Therapeutics
FULC
|
$18.7M |
| 4 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$16.9M |
| 5 |
Structure Therapeutics
GPCR
|
$16.2M |
Top Sells
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$41.8M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
$10.7M |
| 3 |
Mineralys Therapeutics
MLYS
|
$8.66M |
| 4 |
C4 Therapeutics
CCCC
|
$5.9M |
| 5 |
SLN
Silence Therapeutics
SLN
|
$4.76M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Entrada Therapeutics
TRDA
$208M
| $9.35M | 0.79% |
584,955
| – | – |
|
27
VistaGen Therapeutics
VTGN
$102M
| $8.06M | 0.68% |
2,676,580
| – | – |
|
|
28
Tarsus Pharmaceuticals
TARS
$2.47B
| $7.62M | 0.65% |
231,820
-324,497
| -58% | -$10.7M |
|
29
EyePoint Pharmaceuticals
EYPT
$797M
| $7.37M | 0.62% |
922,335
| – | – |
|
30
Nektar Therapeutics
NKTR
$568M
| $5.2M | 0.44% |
4,000,000
| – | – |
|
|
JBIO
31
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $4.68M | 0.4% |
2,240,809
| – | – |
|
32
Avalo Therapeutics
AVTX
$122M
| $4.59M | 0.39% |
+483,000
| New | +$4.59M |
|
33
Kodiak Sciences
KOD
$478M
| $2.63M | 0.22% |
1,008,158
+108,159
| +12% | +$282K |
|
34
AN2 Therapeutics
ANTX
$30.1M
| $1.66M | 0.14% |
1,555,118
| – | – |
|
35
Ventyx Biosciences
VTYX
$171M
| $689K | 0.06% |
316,195
| – | – |
|
36
Cabaletta Bio
CABA
$133M
| $410K | 0.03% |
86,795
| – | – |
|
|
37
C4 Therapeutics
CCCC
$185M
| – | – |
-1,276,574
| Closed | -$5.9M |
|
|
38
Madrigal Pharmaceuticals
MDGL
$9.76B
| – | – |
-149,283
| Closed | -$41.8M |
|